ORIGINAL ARTICLE

Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer

H J Huang¹, P Neven², M Drijkoningen⁴, R Paridaens⁵, H Wildiers⁵, E Van Limbergen⁶, P Berteloot³, F Amant², I Vergote³ and M R Christiaens⁷

¹ Division of Gynaecological Oncology in Department of Obstetrics and Gynaecology, Chang Gung Memorial Hospital, 333 Taoyuan, Taiwan
² Division of Gynaecological Oncology in Department of Obstetrics and Gynaecology and Multidisciplinary Breast Centre, Leuven University Hospital, 3000 Leuven, Belgium
³ Division of Gynaecologic Oncology in Department of Obstetrics and Gynaecology, Leuven University Hospital
⁴ Department of Pathology and Multidisciplinary Breast Centre, Leuven University Hospital
⁵ Department of Medical Oncology and Multidisciplinary Breast Centre, Leuven University Hospital
⁶ Department of Radiotherapy and Multidisciplinary Breast Centre, Leuven University Hospital
⁷ Department of Surgery and Multidisciplinary Breast Centre, Leuven University Hospital

Correspondence to:
Correspondence to:
Dr P Neven
Division of Gynaecological Oncology in Department of Obstetrics and Gynaecology, University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium; Patrick.Neven{at}uz.kuleuven.ac.be

Aims: To investigate the association between tumour characteristics and HER-2/neu by immunohistochemistry in primary operable breast cancer.

Methods: The association between HER-2/neu and other clinicopathological factors was evaluated in 1362 consecutive patients with primary breast cancer treated between 2000 and July 2003 in one centre. Microscopic tumour size, tumour grade, lymph node status, patient’s age, oestrogen receptor (ER), progesterone receptor (PR), and joint ER/PR status were evaluated, using the ² test for univariate analysis and logistic regression for multivariate analysis. The hormone receptors and HER-2/neu were studied immunohistochemically. Using the HER-2/neu DAKO scoring system, scores of 0, 1+, or 2+ were defined as negative and 3+ as positive. Data for DAKO scores 2+/3+ versus 0/1+ are also presented.

Results: Hormone receptor negative breast cancers were more often HER-2/neu positive than hormone receptor positive cancers, both for ER (28.7% v 6.8%) and PR (19.9% v 5.9%). In multivariate analysis, both ER, PR, and tumour grade were independently associated with HER-2/neu. In ER⁺ tumours, HER-2/neu overexpression was significantly lower in PR⁺ than in PR^– cases (11.5% v 5.4%). HER-2/neu overexpression (2.7%) was lowest in the large subgroup of ER⁺PR⁺ tumours with low tumour grade (grade 1–2), comprising 46.1% of all patients.

Conclusions: ER, PR, and tumour grade are independent predictors for HER-2/neu overexpression in women with primary operable breast cancer. ER and PR are negatively associated with HER-2/neu, whereas tumour grade is positively associated with HER-2/neu. In women with ER⁺ tumours, PR status also affects the likelihood of HER-2/neu expression.

Abbreviations: CI, confidence interval; ER, oestrogen receptor; FISH, fluorescence in situ hybridisation; IHC, immunohistochemistry; OR, odds ratio; PR, progesterone receptor

Keywords: breast cancer; immunohistochemistry; HER-2/neu; oestrogen receptor; progesterone receptor

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., Hortobagyi, G. N. (2009). The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine. The Oncologist 14: 320-368 [Abstract] [Full Text]  
• Miller, W. R., Bartlett, J., Brodie, A. M. H., Brueggemeier, R. W., di Salle, E., Lonning, P. E., Llombart, A., Maass, N., Maudelonde, T., Sasano, H., Goss, P. E. (2008). Aromatase Inhibitors: Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter?. The Oncologist 13: 829-837 [Abstract] [Full Text]  
• Neven, P., Brouckaert, O., Van Belle, V., Vanden Bempt, I., Hendrickx, W., Cho, H., Deraedt, K., Van Calster, B., Van Huffel, S., Moerman, P., Amant, F., Leunen, K., Smeets, A., Wildiers, H., Paridaens, R., Vergote, I., Christiaens, M.-R. (2008). In Early-Stage Breast Cancer, the Estrogen Receptor Interacts With Correlation Between Human Epidermal Growth Factor Receptor 2 Status and Age at Diagnosis, Tumor Grade, and Lymph Node Involvement. JCO 26: 1768-1769 [Full Text]  
• Bartlett, J. M.S., Ellis, I. O., Dowsett, M., Mallon, E. A., Cameron, D. A., Johnston, S., Hall, E., A'Hern, R., Peckitt, C., Bliss, J. M., Johnson, L., Barrett-Lee, P., Ellis, P. (2008). In Reply. JCO 26: 1769-1771 [Full Text]  
• Wolff, A. C., Berry, D., Carey, L. A., Colleoni, M., Dowsett, M., Ellis, M., Garber, J. E., Mankoff, D., Paik, S., Pusztai, L., Lou Smith, M., Zujewski, J. (2008). Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer. JCO 26: 806-813 [Abstract] [Full Text]  
• De Maeyer, L., Van Limbergen, E., De Nys, K., Moerman, P., Pochet, N., Hendrickx, W., Wildiers, H., Paridaens, R., Smeets, A., Christiaens, M.-R., Vergote, I., Leunen, K., Amant, F., Neven, P. (2008). Does Estrogen Receptor-Negative/Progesterone Receptor-Positive Breast Carcinoma Exist?. JCO 26: 335-336 [Full Text]  
• Francis, G. D, Dimech, M., Giles, L., Hopkins, A. (2007). Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program. J. Clin. Pathol. 60: 1277-1283 [Abstract] [Full Text]  
• Hicks, D. G., Yoder, B. J., Short, S., Tarr, S., Prescott, N., Crowe, J. P., Dawson, A. E., Budd, G. T., Sizemore, S., Cicek, M., Choueiri, T. K., Tubbs, R. R., Gaile, D., Nowak, N., Accavitti-Loper, M. A., Frost, A. R., Welch, D. R., Casey, G. (2006). Loss of Breast Cancer Metastasis Suppressor 1 Protein Expression Predicts Reduced Disease-Free Survival in Subsets of Breast Cancer Patients.. Clin. Cancer Res. 12: 6702-6708 [Abstract] [Full Text]  
• Kim, H.-J., Cui, X., Hilsenbeck, S. G., Lee, A. V. (2006). Progesterone Receptor Loss Correlates with Human Epidermal Growth Factor Receptor 2 Overexpression in Estrogen Receptor-Positive Breast Cancer. Clin. Cancer Res. 12: 1013s-1018s [Abstract] [Full Text]  
• Arpino, G., Weiss, H., Lee, A. V., Schiff, R., De Placido, S., Osborne, C. K., Elledge, R. M. (2005). Estrogen Receptor-Positive, Progesterone Receptor-Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance. JNCI J Natl Cancer Inst 97: 1254-1261 [Abstract] [Full Text]